<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00028652</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069115</org_study_id>
    <secondary_id>P30CA014520</secondary_id>
    <secondary_id>WCCC-CO-9771</secondary_id>
    <secondary_id>WCCC-HSC-1998-257</secondary_id>
    <secondary_id>NCI-T98-0025</secondary_id>
    <nct_id>NCT00028652</nct_id>
  </id_info>
  <brief_title>Interleukin-12 Gene Therapy in Treating Patients With Skin Metastases</brief_title>
  <official_title>Treament of Spontaneous Tumor Metastases With IL-12 DNA (NSC #709933): A Phase IB Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <brief_summary>
    <textblock>
      RATIONALE: Inserting the gene for interleukin-12 into a person's skin tumor cells may make&#xD;
      the body build an immune response to kill tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of interleukin-12 gene therapy in treating&#xD;
      patients who have skin metastases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and toxicity of interleukin-12 gene in patients with spontaneous&#xD;
           skin metastases.&#xD;
&#xD;
        -  Determine the antitumor immune response in patients treated with this regimen.&#xD;
&#xD;
        -  Compare the toxicity of this regimen administered for 1 week vs 2 weeks in these&#xD;
           patients.&#xD;
&#xD;
        -  Compare the local and systemic antitumor response in patients treated with this regimen&#xD;
           administered for 1 week vs 2 weeks.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to number of tumor sites (1 vs 2 vs 3 or more).&#xD;
      Patients are assigned to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Group A: Patients receive interleukin-12 gene intratumorally over 5 minutes on days 1,&#xD;
           3, and 5.&#xD;
&#xD;
        -  Group B: Patients receive IL-12 gene intratumorally over 5 minutes on days 1, 3, 5, 8,&#xD;
           10, and 12.&#xD;
&#xD;
      Patients with stable or responding disease may receive 1 subsequent course beginning on day&#xD;
      29.&#xD;
&#xD;
      Patients are followed at 3, 6, and 12 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12 patients (6 per treatment group) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>January 2002</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Metastatic Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>interleukin-12 gene</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed solid malignancy&#xD;
&#xD;
               -  Surgically or medically incurable disease&#xD;
&#xD;
               -  No standard chemotherapy or radiotherapy exists for this disease&#xD;
&#xD;
          -  Tumor of at least 0.5 cm but no more than 2.5 cm infiltrating into or underlying the&#xD;
             skin&#xD;
&#xD;
               -  Cutaneous metastases, subcutaneous metastases, or tumor-involved lymph nodes that&#xD;
                  are easily palpable&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC greater than 3,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 80,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 2.0 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active infections requiring antibiotic, antiviral, or antifungal treatment&#xD;
&#xD;
          -  No other active malignancy&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 1 month since prior immunotherapy&#xD;
&#xD;
          -  No concurrent colony-stimulating factors&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 1 month since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 1 month since prior steroids (other than intermittent use as an antiemetic or&#xD;
             topical agent)&#xD;
&#xD;
          -  No concurrent steroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior radiotherapy to vaccine site allowed provided there is documentation of&#xD;
             progressive disease&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior organ allografts&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent antineoplastic therapy&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M. Mahvi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-6164</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>January 4, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 12, 2019</last_update_submitted>
  <last_update_submitted_qc>December 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>skin metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-12</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

